We use cookies for a better user experience. Read our Privacy Policy

I Agree

Cancer Biomarkers Market

Cancer Biomarkers Market (Type: Protein, Genetics, and Others; and Type of Cancer: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Ovarian, Liver, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Cancer Biomarkers Market Outlook 2031

  • The global cancer biomarkers market was valued at US$ 12.6 Bn in 2021
  • The market is projected to advance at a CAGR of 9.9% from 2022 to 2031
  • The global cancer biomarkers market is anticipated to reach more than US$ 31.4 Bn by 2031

Analysts’ Viewpoint on Cancer Biomarkers Market Scenario

Cancer biomarkers play an important role in the early diagnosis of cancer and personalization of cancer treatments. Increase in prevalence of various types of cancers, rise in geriatric population across the world, and growth in technological advancements in development of cancer biomarkers are some of the key factors expected to drive the global cancer biomarkers market during the forecast period. Increase in usage of CEA biomarkers and HER2 biomarkers for detection of cancers such as breast cancer, ovary cancer, thyroid cancer, and small cell lung cancer is also projected to drive the market in the next few years. Leading players are focusing on research and development activities in biomarkers to gain lucrative revenue opportunities in the global cancer biomarkers market.

Cancer Biomarkers Market

Cancer Biomarkers Market Introduction

Biomarker, or biological marker, is a measurable indicator of some biological state or condition. Cancer biomarkers are biomolecules that can be used to determine the cancer in the body. According to the World Health Organization, cancer is a leading cause of death worldwide; it accounted for nearly 10 million deaths or nearly one in six deaths in 2020. Lung, breast, colon, rectum, and prostate cancers are some of the common cancers. According to a study published in the Journal of Ovarian Research, ovarian cancer is currently the fifth leading cause of death for women with cancer globally. More than 70% of cases of this cancer are diagnosed at an advanced stage. The human epididymis protein 4 biomarker test (HE4 test) is considered to be the most effective and reliable test for the detection of ovarian and endometrial cancers.

Request a sample to get extensive insights into the Cancer Biomarkers Market

Increase in Cancer Cases Worldwide to Drive Demand for Cancer Biomarkers

Wide prevalence of cancer is a key driver of the global cancer biomarkers market. According to a World Health Organization report, cancer is the major reason for deaths around the globe after heart issues. Cancer cases are surging due to the increase in trend of smoking, rise in pollution levels, and poor dietary habits. Around 235,760 lung cancer cases were reported in the U.S. in 2021. Furthermore, more than 130,000 people lose their lives every year due to lung cancer in the U.S. Lung cancer cases have been rising in other parts of the world as well, with percentage of people smoking reaching around 19% globally. Around one-third of deaths from cancer are linked to tobacco usage, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.

Potential Pipeline Candidates to Offer Lucrative Opportunities to Market Vendors

Many pharmaceutical companies are actively investing in the research and development of novel biomarkers for cancer diagnosis and treatment. Various potential candidates are nearing the end of their development. This is expected to significantly boost the market. According to the National Library of Medicine, approximately 1,515 cancer biomarkers are in clinical trials. For instance, Lund University Hospital, in collaboration with the South Sweden Breast Cancer Group, is conducting clinical trials to compare the efficacy and tolerability of atorvastatin (in phase 2). Introduction of new biomarkers for cancer screening and diagnosis is expected to propel the oncology biomarkers market growth. Additionally, increase in product launches and diagnostics pertaining to cancer biomarkers is estimated to drive the market. For instance, in April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various types of cancers.

Request a custom report on Cancer Biomarkers Market

Increase in Adoption of Protein Biomarkers for Accurate Diagnosis of Cancer

In terms of type, the global cancer biomarkers market has been classified into protein, genetic, and others. The protein segment held major share of the global market in 2021. The segment is expected to maintain its leading position in the global cancer biomarkers market during the forecast period. This can be ascribed to the increase in usage of protein biomarkers in research in cancer treatment. Protein biomarkers are considered the most common biomarkers used for the accurate detection of various types of cancers.

Rise in Incidence of Breast Cancer Across Globe

Based on type of cancer, the global cancer biomarkers market has been segmented into lung, breast, leukemia, melanoma, colorectal, prostate, ovarian, liver, and others. The breast cancer segment is projected to dominate the global market during the forecast period. Biomarkers are extensively used to detect breast cancer in patients. Increase in number of patients suffering from breast cancer across the globe is expected to drive the segment during the forecast period. According to the World Health Organization, breast cancer was the most common cancer across the globe in 2021, accounting for 12% of all new annual cancer cases worldwide.

High Efficiency of Omics Technology in Early Diagnosis of Cancer

In terms of profiling technology, the global cancer biomarkers market has been classified into omics, imaging, immunoassay, bioinformatics, and others. The omics segment held dominant share of the market in 2021. The segment is expected to grow at a faster pace during the forecast period. Omics technology is highly efficient in the early diagnosis of cancer. Additionally, novel development in profiling technologies for cancer biomarkers is expected to drive the cancer biomarker market size during the forecast period.

Regional Outlook of Global Cancer Biomarkers Market

North America dominated the global cancer biomarkers market, with more than 30% share in 2021. It is expected to hold major share of the global cancer biomarkers market during the forecast period. High patient population with cancer in the U.S. and Canada and increase in research and development activities in various types of cancer biomarkers are expected to drive the cancer biomarkers market in the region.

Europe is also expected to be a highly attractive region of the global cancer biomarkers market during the forecast period. Increase in prevalence and incidence of cancer in the region is likely to drive the market during the forecast period.

The cancer biomarkers market in Asia Pacific is also anticipated to grow significantly during the forecast period. This can be ascribed to the rise in disposable income, rapid urbanization, increase in health care infrastructure, and distribution and partnership strategies adopted by the players in the region.

Analysis of Key Players in Global Cancer Biomarkers Market

The global cancer biomarkers market is consolidated, with the top players accounting for major share. Players are focusing on adopting strategies such as acquisition & collaboration, geographic expansion, growth of distribution channels, and R&D to enhance their share in the global cancer biomarkers market. Key players operating in the global cancer biomarkers market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Merck & Co, Inc., Thermo Fisher Scientific, Inc., Bristol-Myers Squibb Company, PerkinElmer, Inc., Qiagen N.V., Siemens AG, Exact Sciences Corporation, Novartis AG, Bio-Rad Laboratories, Illumina, Agilent Technologies Inc., Hologic, Inc., and bioMérieux SA.

Key Developments in Global Cancer Biomarkers Market

  • In January 2022, a University of Oxford study published in the Clinical Cancer Research Journal defined a new type of blood test that can be used to detect a range of cancers and their spread throughout the body. The study had a sample size of 300 patients, with non-specific but concerning symptoms of cancer such as fatigue and weight loss. According to the study, cancer was correctly detected in 19 out of every 20 patients that used the test. In those with cancer, metastatic disease was identified with an overall accuracy of 94%.
  • In June 2021, Hill's Pet Nutrition announced plans to invest more than US$ 250 Mn in building a new factory in Leavenworth County in its home state of Kansas in order to cater to the rise in demand for its pet nutrition supplements
  • In December 2020, the FDA approved Thermo Fisher Scientific’s NGS-based companion diagnostic for EGFR Exon20 insertion mutant to help identify non-small cell lung cancer tumor tissue

Each of these players has been profiled in the cancer biomarkers market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Cancer Biomarkers Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 12.6 Bn

Market Forecast Value in 2031

More than US$ 31.4 Bn

Growth Rate

(CAGR)

9.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, and key trend analysis.

Competition Landscape

  • Market share analysis by the company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Protein
    • Genetic
    • Others
  • Type of Cancer
    • Lung
    • Breast
    • Leukemia
    • Melanoma
    • Colorectal
    • Prostate
    • Ovarian
    • Liver
    • Others
  • Profiling Technology
    • Omics
    • Imaging
    • Immunoassay
    • Bioinformatics
    • Others
  • Application
    • Diagnostics
    • R&D
    • Prognostics
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • F. Hoffmann-LA Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Merck & Co, Inc.
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Siemens AG
  • Exact Sciences Corporation
  • Novartis AG
  • Bio-Rad Laboratories
  • Illumina
  • Agilent Technologies Inc.
  • Hologic, Inc.
  • bioMérieux SA

Customization Scope

Available upon request

Pricing

Available upon request

Cancer Biomarkers Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global cancer biomarkers market in 2021?

The global cancer biomarkers market was valued at US$ 12.6 Bn in 2021

How big will be the global cancer biomarkers market in 2031?

The global cancer biomarkers market is projected to reach more than US$ 31.4 Bn by 2031

What was the CAGR of the global cancer biomarkers market from 2017–2021?

The global cancer biomarkers market grew at a CAGR of 4.5% from 2017 to 2021

What will be the CAGR of the global cancer biomarkers market during the forecast period (2022–2031)?

The global cancer biomarkers market is anticipated to grow at a CAGR of 9.9% from 2022 to 2031

Which are the prominent trends that affect the market growth?

Increase in patient population with various type of cancers, rise in geriatric population across the globe, and increase in technological advancements in development of cancer biomarkers

What was the market share of the leading segment of the global cancer biomarkers market?

The protein type segment accounted for more than 50% share of the global cancer biomarkers market in 2021

Which region will account for the major share of the global market during the forecast period?

North America is expected to account for major share of the global cancer biomarkers market during the forecast period

Who are the prominent players in the global cancer biomarkers market?

F. Hoffmann-LA Roche Ltd., Thermo Fisher Scientific, Inc., Abbott Laboratories, Merck & Co., Inc Bristol-Myers Squibb Company, PerkinElmer, Inc., Qiagen N.V., Siemens AG, Exact Sciences Corporation, Novartis AG, Bio-Rad Laboratories, Illumina, Agilent Technologies Inc., Hologic, Inc., and bioMérieux SA

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Biomarkers Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cancer Biomarkers Market Analysis and Forecasts, 2017 - 2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Technological Advancements

    5.2. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)

    5.3. Regulatory Scenario by Region/Globally

    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Cancer Biomarkers Market Analysis and Forecasts, By Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Type, 2017 - 2031

        6.3.1. Protein

        6.3.2. Genetic

        6.3.3. Others

    6.4. Market Attractiveness By Type

7. Global Cancer Biomarkers Market Analysis and Forecasts, By Type of Cancer

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By Type of Cancer, 2017 - 2031

        7.3.1. Lung

        7.3.2. Breast

        7.3.3. Leukemia

        7.3.4. Melanoma

        7.3.5. Colorectal

        7.3.6. Prostate

        7.3.7. Ovarian

        7.3.8. Liver

        7.3.9. Others

    7.4. Market Attractiveness By Type of Cancer

8. Global Cancer Biomarkers Market Analysis and Forecasts, By Profiling Technology

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast By Profiling Technology, 2017 - 2031

        8.3.1. Omics

        8.3.2. Imaging

        8.3.3. Immunoassay

        8.3.4. Bioinformatics

        8.3.5. Others

    8.4. Market Attractiveness By Profiling Technology

9. Global Cancer Biomarkers Market Analysis and Forecasts, By Application

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast By Application, 2017 - 2031

        9.3.1. Diagnostics

        9.3.2. R&D

        9.3.3. Prognostics

        9.3.4. Others

    9.4. Market Attractiveness By Application

10. Global Cancer Biomarkers Market Analysis and Forecasts, By Region

    10.1. Key Findings

    10.2. Market Value Forecast By Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness By Country/Region

11. North America Cancer Biomarkers Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast By Type, 2017 - 2031

        11.2.1. Protein

        11.2.2. Genetic

        11.2.3. Others

    11.3. Market Value Forecast By Type of Cancer, 2017 - 2031

        11.3.1. Lung

        11.3.2. Breast

        11.3.3. Leukemia

        11.3.4. Melanoma

        11.3.5. Colorectal

        11.3.6. Prostate

        11.3.7. Ovarian

        11.3.8. Liver

        11.3.9. Others

    11.4. Market Value Forecast By Profiling Technology, 2017 - 2031

        11.4.1. Omics

        11.4.2. Imaging

        11.4.3. Immunoassay

        11.4.4. Bioinformatics

        11.4.5. Others

    11.5. Market Value Forecast By Application, 2017 - 2031

        11.5.1. Diagnostics

        11.5.2. R&D

        11.5.3. Prognostics

        11.5.4. Others

    11.6. Market Value Forecast By Country, 2017 - 2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Type

        11.7.2. By Type of Cancer

        11.7.3. By Profiling Technology

        11.7.4. By Application

        11.7.5. By Country

12. Europe Cancer Biomarkers Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast By Type, 2017 - 2031

        12.2.1. Protein

        12.2.2. Genetic

        12.2.3. Others

    12.3. Market Value Forecast By Type of Cancer, 2017 - 2031

        12.3.1. Lung

        12.3.2. Breast

        12.3.3. Leukemia

        12.3.4. Melanoma

        12.3.5. Colorectal

        12.3.6. Prostate

        12.3.7. Ovarian

        12.3.8. Liver

        12.3.9. Others

    12.4. Market Value Forecast By Profiling Technology, 2017 - 2031

        12.4.1. Omics

        12.4.2. Imaging

        12.4.3. Immunoassay

        12.4.4. Bioinformatics

        12.4.5. Others

    12.5. Market Value Forecast By Application, 2017 - 2031

        12.5.1. Diagnostics

        12.5.2. R&D

        12.5.3. Prognostics

        12.5.4. Others

    12.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Type of Cancer

        12.7.3. By Profiling Technology

        12.7.4. By Application

        12.7.5. By Country/Sub-region

13. Asia Pacific Cancer Biomarkers Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast By Type, 2017 - 2031

        13.2.1. Protein

        13.2.2. Genetic

        13.2.3. Others

    13.3. Market Value Forecast By Type of Cancer, 2017 - 2031

        13.3.1. Lung

        13.3.2. Breast

        13.3.3. Leukemia

        13.3.4. Melanoma

        13.3.5. Colorectal

        13.3.6. Prostate

        13.3.7. Ovarian

        13.3.8. Liver

        13.3.9. Others

    13.4. Market Value Forecast By Profiling Technology, 2017 - 2031

        13.4.1. Omics

        13.4.2. Imaging

        13.4.3. Immunoassay

        13.4.4. Bioinformatics

        13.4.5. Others

    13.5. Market Value Forecast By Application, 2017 - 2031

        13.5.1. Diagnostics

        13.5.2. R&D

        13.5.3. Prognostics

        13.5.4. Others

    13.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Type

        13.7.2. By Type of Cancer

        13.7.3. By Profiling Technology

        13.7.4. By Application

        13.7.5. By Country/Sub-region

14. Latin America Cancer Biomarkers Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast By Type, 2017 - 2031

        14.2.1. Protein

        14.2.2. Genetic

        14.2.3. Others

    14.3. Market Value Forecast By Type of Cancer, 2017 - 2031

        14.3.1. Lung

        14.3.2. Breast

        14.3.3. Leukemia

        14.3.4. Melanoma

        14.3.5. Colorectal

        14.3.6. Prostate

        14.3.7. Ovarian

        14.3.8. Liver

        14.3.9. Others

    14.4. Market Value Forecast By Profiling Technology, 2017 - 2031

        14.4.1. Omics

        14.4.2. Imaging

        14.4.3. Immunoassay

        14.4.4. Bioinformatics

        14.4.5. Others

    14.5. Market Value Forecast By Application, 2017 - 2031

        14.5.1. Diagnostics

        14.5.2. R&D

        14.5.3. Prognostics

        14.5.4. Others

    14.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Type of Cancer

        14.7.3. By Profiling Technology

        14.7.4. By Application

        14.7.5. By Country/Sub-region

15. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast By Type, 2017 - 2031

        15.2.1. Protein

        15.2.2. Genetic

        15.2.3. Others

    15.3. Market Value Forecast By Type of Cancer, 2017 - 2031

        15.3.1. Lung

        15.3.2. Breast

        15.3.3. Leukemia

        15.3.4. Melanoma

        15.3.5. Colorectal

        15.3.6. Prostate

        15.3.7. Ovarian

        15.3.8. Liver

        15.3.9. Others

    15.4. Market Value Forecast By Profiling Technology, 2017 - 2031

        15.4.1. Omics

        15.4.2. Imaging

        15.4.3. Immunoassay

        15.4.4. Bioinformatics

        15.4.5. Others

    15.5. Market Value Forecast By Application, 2017 - 2031

        15.5.1. Diagnostics

        15.5.2. R&D

        15.5.3. Prognostics

        15.5.4. Others

    15.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Type

        15.7.2. By Type of Cancer

        15.7.3. By Profiling Technology

        15.7.4. By Application

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of companies)

    16.2. Market Share/Ranking Analysis By Company (2021)

    16.3. Company Profiles

        16.3.1. F. Hoffmann-LA Roche Ltd.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Product Portfolio

            16.3.1.3. SWOT Analysis

            16.3.1.4. Strategic Overview

        16.3.2. Thermo Fisher Scientific, Inc.

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Product Portfolio

            16.3.2.3. SWOT Analysis

            16.3.2.4. Strategic Overview

        16.3.3. Abbott Laboratories

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Product Portfolio

            16.3.3.3. SWOT Analysis

            16.3.3.4. Strategic Overview

        16.3.4. Bristol-Myers Squibb Company

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Product Portfolio

            16.3.4.3. SWOT Analysis

            16.3.4.4. Strategic Overview

        16.3.5. PerkinElmer, Inc.

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Product Portfolio

            16.3.5.3. SWOT Analysis

            16.3.5.4. Strategic Overview

        16.3.6. Qiagen N.V.

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Product Portfolio

            16.3.6.3. SWOT Analysis

            16.3.6.4. Strategic Overview

        16.3.7. Siemens AG

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Product Portfolio

            16.3.7.3. SWOT Analysis

            16.3.7.4. Strategic Overview

        16.3.8. Exact Sciences Corporation

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Product Portfolio

            16.3.8.3. SWOT Analysis

            16.3.8.4. Strategic Overview

        16.3.9. Novartis AG

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Product Portfolio

            16.3.9.3. SWOT Analysis

            16.3.9.4. Strategic Overview

        16.3.10. Bio-Rad Laboratories

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Product Portfolio

            16.3.10.3. SWOT Analysis

            16.3.10.4. Strategic Overview

        16.3.11. Illumina

            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.11.2. Product Portfolio

            16.3.11.3. SWOT Analysis

            16.3.11.4. Strategic Overview

        16.3.12. Agilent Technologies Inc.

            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.12.2. Product Portfolio

            16.3.12.3. SWOT Analysis

            16.3.12.4. Strategic Overview

        16.3.13. Hologic, Inc.

            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.13.2. Product Portfolio

            16.3.13.3. SWOT Analysis

            16.3.13.4. Strategic Overview

        16.3.14. bioMérieux SA

            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.14.2. Product Portfolio

            16.3.14.3. SWOT Analysis

            16.3.14.4. Strategic Overview

List of Tables

Table 01: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 02: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

Table 03: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 04: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 05: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 08: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

Table 09: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 10: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 11: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 13: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

Table 14: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 15: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 18: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

Table 19: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 20: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 21: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 23: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

Table 24: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 25: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 26: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 28: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

Table 29: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 30: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

List of Figures

Figure 01: Global Cancer Biomarkers market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Cancer Biomarkers market Value Share, by Type, 2021

Figure 03: Global Cancer Biomarkers market Value Share, by Profiling Technology, 2021

Figure 04: Global Cancer Biomarkers market Value Share, by Cancer, 2021

Figure 05: Global Cancer Biomarkers market Value Share, by Application, 2021

Figure 06: Global Cancer Biomarkers market Value Share, by Region, 2021

Figure 07: Global Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure 08: Global Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

Figure 09: Global Cancer Biomarkers Market Value (US$ Mn), by Protein, 2017‒2031

Figure 10: Global Cancer Biomarkers Market Value (US$ Mn), by Genetic, 2017‒2031

Figure 11: Global Cancer Biomarkers Market Value (US$ Mn), by Others, 2017‒2031

Figure 12: Global Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

Figure 13: Global Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

Figure 14: Global Cancer Biomarkers Market Revenue (US$ Mn), by Lung, 2017–2031

Figure 15: Global Cancer Biomarkers Market Revenue (US$ Mn), by Breast, 2017–2031

Figure 16: Global Cancer Biomarkers Market Revenue (US$ Mn), by Leukemia, 2017–2031

Figure 17: Global Cancer Biomarkers Market Revenue (US$ Mn), by Melonoma, 2017–2031

Figure 18: Global Cancer Biomarkers Market Revenue (US$ Mn), by Colorectal, 2017–2031

Figure 19: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prostate, 2017–2031

Figure 20: Global Cancer Biomarkers Market Revenue (US$ Mn), by Ovarian, 2017–2031

Figure 21: Global Cancer Biomarkers Market Revenue (US$ Mn), by Liver, 2017–2031

Figure 22: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017–2031

Figure 23: Global Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

Figure 24: Global Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

Figure 25: Global Cancer Biomarkers Market Revenue (US$ Mn), by Omics, 2017–2031

Figure 26: Global Cancer Biomarkers Market Revenue (US$ Mn), by Imaging, 2017–2031

Figure 27: Global Cancer Biomarkers Market Revenue (US$ Mn), by Immunoassay, 2017–2031

Figure 28: Global Cancer Biomarkers Market Revenue (US$ Mn), by Bioinformatics, 2017–2031

Figure 29: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017–2031

Figure 30: Global Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

Figure 31: Global Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Figure 32: Global Cancer Biomarkers Market Revenue (US$ Mn), by Diagnostics, 2017–2031

Figure 33: Global Cancer Biomarkers Market Revenue (US$ Mn), by R&D, 2017–2031

Figure 34: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prognostics, 2017–2031

Figure 35: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017–2031

Figure 36: Global Cancer Biomarkers Market Value Share Analysis, by Region, 2021 and 2031

Figure 37: Global Cancer Biomarkers Market Attractiveness Analysis, by Region, 2022–2031

Figure 38: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

Figure 39: North America Cancer Biomarkers Market Value Share Analysis, by Country, 2021 and 2031

Figure 40: North America Cancer Biomarkers Market Attractiveness Analysis, by Country, 2022–2031 

Figure 41: North America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure 42: North America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

Figure 43: North America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

Figure 44: North America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

Figure 45: North America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

Figure 46: North America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

Figure 47: North America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

Figure 48: North America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Figure 49: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

Figure 50: Europe Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 51: Europe Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 52: Europe Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure53 11: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

Figure 54: Europe Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

Figure 55: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

Figure 56: Europe Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

Figure 57: Europe Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

Figure 58: Europe Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

Figure 59: Europe Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Figure 60: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

Figure 61: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 62: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 63: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure 64: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

Figure 65: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

Figure 66: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

Figure 67: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

Figure 68: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

Figure 69: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

Figure 70: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Figure 71: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

Figure 72: Latin America Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031

Figure 73: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 74: Latin America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure 75: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

Figure 76: Latin America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

Figure 77: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

Figure 78: Latin America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

Figure 79: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

Figure 80: Latin America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

Figure 81: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Figure 82: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

Figure 83: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031

Figure 84: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 85: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure 86: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

Figure 87: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

Figure 88: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

Figure 89: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

Figure 90: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

Figure 91: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

Figure 92: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

409

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved